Omeros Corporation (OMER) Set to Announce Quarterly Earnings on Tuesday
Omeros Corporation (NASDAQ:OMER) is set to issue its quarterly earnings data after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.
Omeros Corporation (NASDAQ:OMER) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.12. The firm had revenue of $17.15 million during the quarter, compared to analyst estimates of $14.63 million. The firm’s quarterly revenue was up 71.5% on a year-over-year basis. During the same period last year, the business posted ($0.32) earnings per share. On average, analysts expect Omeros Corporation to post $-1.32 EPS for the current fiscal year and $-0.61 EPS for the next fiscal year.
Shares of Omeros Corporation (NASDAQ:OMER) opened at 15.75 on Tuesday. The stock has a 50 day moving average price of $19.91 and a 200 day moving average price of $19.52. The firm’s market capitalization is $705.65 million. Omeros Corporation has a 1-year low of $8.06 and a 1-year high of $27.09.
TRADEMARK VIOLATION NOTICE: “Omeros Corporation (OMER) Set to Announce Quarterly Earnings on Tuesday” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/31/omeros-corporation-omer-set-to-announce-quarterly-earnings-on-tuesday.html.
Several research analysts have recently issued reports on OMER shares. Cantor Fitzgerald reiterated a “hold” rating and set a $19.00 price target (up from $15.00) on shares of Omeros Corporation in a report on Thursday, August 24th. Maxim Group reiterated a “buy” rating and set a $24.00 price target (up from $23.00) on shares of Omeros Corporation in a report on Tuesday, August 8th. Zacks Investment Research upgraded shares of Omeros Corporation from a “hold” rating to a “strong-buy” rating and set a $22.00 price target for the company in a report on Thursday, October 19th. Finally, Wedbush reiterated an “outperform” rating and set a $47.00 price target on shares of Omeros Corporation in a report on Friday, August 18th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Omeros Corporation has an average rating of “Buy” and a consensus price target of $34.83.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.